An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10mg in Subjects With MS

The purpose of this study is to determine changes on overall gait as well as in multiple gait and balance parameters after withdrawal of dalfampridine-ER 10mg in MS subjects who are receiving the medication consistently for at least two weeks prior to screening.

Longitudinal study design

Inclusion Criteria:

• Diagnosis of multiple sclerosis
• Receiving Ampyra® consistently for at least 2 weeks prior to the screening visit
• No history of seizures except simple febrile seizures

Exclusion Criteria:

• Sexually active woman of childbearing potential who is not surgically sterile, <two years post-menopause or is not using effective birth control methods
• Subject who is pregnant or breastfeeding